Matches in DBpedia 2014 for { ?s ?p Asenapine (USAN, rINNM and BANM; trade names Saphris (AU, US), Sycrest (EU, UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Asenapine comment "Asenapine (USAN, rINNM and BANM; trade names Saphris (AU, US), Sycrest (EU, UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel.".